Autoimmune encephalitis: ItsME Foundation funds Harschnitz Group
The Harschnitz Group has been awarded a grant from the ItsME Foundation to develop a human pluripotent stem cell (hPSC)-derived brainstem model to understand brainstem encephalitis. The ItsME Foundation was founded in 2019 by Jur Deitmers and has its base in The Netherlands, with the goal to fight Meningitis and Encephalitis.
Autoimmune encephalitis (AIE) is a group of disorders where the immune system mistakenly attacks healthy brain cells, causing inflammation. Symptoms range from memory loss to seizures and psychiatric issues.
The study will leverage hPSC technology to create disease-relevant cells of the central nervous system, in particular the brainstem, which are less understood in AIE pathology. This approach, utilising advanced stem cell techniques, promises insights into AIE pathogenesis and potential therapeutic avenues, reducing reliance on animal models.
“Our goal is to develop a novel model of the human brainstem, that can be leveraged to study both the normal development of the brain as well as pathology affecting the brainstem” – Oliver Harschnitz explains – “At HT, we will work closely with the National Facility for Genomics, which will help us to profile at a single-cell resolution the fidelity of our model. This project is important to our goals to further understand the molecular mechanisms underlying pathology of the human brainstem. We will do this using multiple single-cell profiling methods that will help us to dissect the cell-type vulnerability within the brainstem for specific autoantibodies.“
Share:
You could also like:
-
Italy at the centre of the Genome of Europe project
The Human Technopole, ELIXIR Italia, the national node of the European life sciences research infrastructure coordinated by the National Research Council (CNR), and the Centro Cardiologico Monzino, as the Italian coordinating centre, have been selected as the Italian partners of Genome of Europe (GoE), the largest EU-funded genomic project, whose ultimate goal is to make […]
-
Human Technopole wins 2024 Oscar di Bilancio
On Friday 13 December, at Palazzo Mezzanotte in Milan, the Human Technopole Foundation’s ‘Integrated Report 2023’ received the Oscar di Bilancio in the social enterprises and non-profit organisations category. The award was presented to President Gianmario Verona, Elena Trovesi, Head of Administration, as well as the project leaders Giovanni Selmi, Head of Finance, and Alessandro […]
-
Mosaic Organoids to Study the Brains of Multiple Patients Simultaneously
An international team of scientists from Human Technopole and the University of Milan has developed and validated an innovative approach to studying human brain development across multiple individuals simultaneously using single organoids—laboratory models that replicate key cellular processes of human neurodevelopment. The research paves the way for in vitro population studies. Additionally, the scientists have developed a novel computational method to more accurately quantify the genetic identity of individual cells profiled from multiple individuals concurrently. The findings have been published in Nature Methods.
-
Cancer stem cell morphology predicts glioblastoma growth and resistance
Human Technopole researchers have identified adducin-γ (ADD3) as a crucial regulator of glioblastoma cancer stem cell morphology and intercellular bridges between tumour cells. These connections facilitate communication and allow tumour cells to share resources, evade chemotherapy, and survive in challenging conditions. The study has been funded by AIRC and the findings are published in Life Science Alliance.
-
Colorectal Cancer: ML Enhances Cetuximab Response Predictions
An international collaborative study led by Human Technopole, Candiolo Cancer Institute IRCCS in Turin, the University of Turin, and the Wellcome Sanger Institute in Cambridge (UK) has identified new factors associated with therapeutic response in colorectal cancer. The research has led to the development of a machine-learning model capable of accurately predicting the effects of cetuximab, a drug in clinical use, on different colorectal tumour subtypes. Funded by the AIRC Foundation, the study paves the way to identifying molecular features that could serve as biomarkers for predicting treatment response in patients with this type of cancer.